MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests

Phase 3positiveremigromigLucentisPositive

AI Analysis

Summary

MSD's remigromig demonstrated non-inferiority to Lucentis in a late-stage study for diabetic macular edema, potentially challenging existing anti-VEGF therapies. Tolerability concerns remain to be addressed.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

remigromig demonstrated non-inferiority to Lucentis in efficacy for DME, though tolerability questions remain

Importance:7/10

Sentiment:

0.60

Phase 3DMEanti-VEGFefficacylate-stage study

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 24, 2026 3:32 PM

Read Original